IBA - Transparency Notification

Corporate
/
13.04.2018

Louvain-la-Neuve, Belgium, April 13, 2018, 17.35 - IBA (Ion Beam Applications SA), the world’s leading provider of proton therapy solutions for the treatment of cancer, announces that it has to issue a transparency notification, in accordance with Article 14, al. 1 of the Transparency Law of May 2, 2007 on disclosure of major holdings, further to the notification received on April 11, 2018.

Reason for the notification: 3% Downwards crossing further to the disposal of voting rights

Persons subject to the notification requirementIBA SA, issuer

Persons that dispose of voting rights: Kempen Capital Management NV

Transaction date06/04/2018

Threshold that is crossed (in %)3% Downwards crossing further to the disposal of voting rights

Denominator29 962 246

Voting rights (number)875 388

Voting rights (%)2,92%

Chain of controlVan Lanschot Kempen N.V. <100%> F. van Lanschot Bankiers N.V. <100%> Kempen & Co N.V. <100%> Kempen Capital Management N.V. Kempen refers to the independence declaration (dated 15 November 2017)

Additional informationKempen Capital Management N.V.appeals for Art. 11 of the (Transparency) Law (May 2, 2007), by which an exemption is acquired

About IBA

IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA’s proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,500 people worldwide, IBA has installed systems across the world.

 IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at: www.iba-worldwide.com

 

For further information, please contact:

 

IBA

Stephanie Bauwin Legal Counsel +32 10 203 924 Stephanie.bauwin@iba-group.com

Share
Download